These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 23204175)

  • 41. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis.
    Jefferson T; Jones M; Doshi P; Del Mar C
    BMJ; 2009 Dec; 339():b5106. PubMed ID: 19995812
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 2009 pandemic influenza A (H1N1) in pregnancy: a systematic review of the literature.
    Mosby LG; Rasmussen SA; Jamieson DJ
    Am J Obstet Gynecol; 2011 Jul; 205(1):10-8. PubMed ID: 21345415
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oseltamivir boosts 2009 H1N1 virus infectivity in vitro.
    Lin X; Zhou J; Zhang Y; Wu J; Zhang F; Li Z; Zhang Y; Bi S; Shu Y; Wang Y
    Biochem Biophys Res Commun; 2009 Dec; 390(4):1305-8. PubMed ID: 19879239
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of influenza with neuraminidase inhibitors.
    Beard KR; Brendish NJ; Clark TW
    Curr Opin Infect Dis; 2018 Dec; 31(6):514-519. PubMed ID: 30320639
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An I436N substitution confers resistance of influenza A(H1N1)pdm09 viruses to multiple neuraminidase inhibitors without affecting viral fitness.
    Kwon JJ; Choi WS; Jeong JH; Kim EH; Lee OJ; Yoon SW; Hwang J; Webby RJ; Govorkova EA; Choi YK; Baek YH; Song MS
    J Gen Virol; 2018 Mar; 99(3):292-302. PubMed ID: 29493493
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Increased virulence of neuraminidase inhibitor-resistant pandemic H1N1 virus in mice: potential emergence of drug-resistant and virulent variants.
    Song MS; Hee Baek Y; Kim EH; Park SJ; Kim S; Lim GJ; Kwon HI; Pascua PN; Decano AG; Lee BJ; Kim YI; Webby RJ; Choi YK
    Virulence; 2013 Aug; 4(6):489-93. PubMed ID: 23924955
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Neuraminidase inhibitors for preventing and treating influenza in adults and children.
    Jefferson T; Jones MA; Doshi P; Del Mar CB; Hama R; Thompson MJ; Spencer EA; Onakpoya I; Mahtani KR; Nunan D; Howick J; Heneghan CJ
    Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD008965. PubMed ID: 24718923
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Y155H amino acid substitution in influenza A(H1N1)pdm09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitors.
    Perez-Sautu U; Pozo F; Cuesta I; Monzon S; Calderon A; Gonzalez M; Molinero M; Lopez-Miragaya I; Rey S; Cañizares A; Rodriguez G; Gonzalez-Velasco C; Lackenby A; Casas I
    Euro Surveill; 2014 Jul; 19(27):14-20. PubMed ID: 25033052
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
    Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H
    Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance.
    McKimm-Breschkin JL
    Influenza Other Respir Viruses; 2013 Jan; 7 Suppl 1(Suppl 1):25-36. PubMed ID: 23279894
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro neuraminidase inhibitory concentration (IC
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S; Ishikawa Y; Yamaguchi H; Shiosakai K
    J Infect Chemother; 2018 Sep; 24(9):707-712. PubMed ID: 29759897
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.
    Kawai N; Ikematsu H; Hirotsu N; Maeda T; Kawashima T; Tanaka O; Yamauchi S; Kawamura K; Matsuura S; Nishimura M; Iwaki N; Kashiwagi S
    Clin Infect Dis; 2009 Dec; 49(12):1828-35. PubMed ID: 19911968
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness of neuraminidase inhibitors in preventing hospitalization during the H1N1 influenza pandemic in British Columbia, Canada.
    Marra F; Chong M; Henry B; Patrick DM; Kendall P
    J Antimicrob Chemother; 2014 May; 69(5):1397-406. PubMed ID: 24346762
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The truth about Tamiflu? Neuraminidase inhibitors in pandemic A/H1N1 flu.
    Weber JT; Nicoll A; Bridges CB; Ciancio BC
    BMJ; 2010 Jan; 340():c130. PubMed ID: 20071425
    [No Abstract]   [Full Text] [Related]  

  • 55. The effect of neuraminidase inhibitors on household transmission in Japanese patients with influenza A and B infection: A prospective, observational study.
    Hirotsu N; Saisho Y; Hasegawa T
    Influenza Other Respir Viruses; 2019 Mar; 13(2):123-132. PubMed ID: 29989680
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characterization of neuraminidase inhibitor-resistant influenza A(H1N1)pdm09 viruses isolated in four seasons during pandemic and post-pandemic periods in Japan.
    Takashita E; Fujisaki S; Kishida N; Xu H; Imai M; Tashiro M; Odagiri T;
    Influenza Other Respir Viruses; 2013 Nov; 7(6):1390-9. PubMed ID: 23745712
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
    Wolkewitz M; Schumacher M
    Lancet Respir Med; 2014 Jul; 2(7):e8-9. PubMed ID: 24948434
    [No Abstract]   [Full Text] [Related]  

  • 58. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
    Jones M; Del Mar C; Hama R
    Lancet Respir Med; 2014 Jul; 2(7):e9-e10. PubMed ID: 24948431
    [No Abstract]   [Full Text] [Related]  

  • 59. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
    Leonardi-Bee J; Venkatesan S; Muthuri SG; Nguyen-Van-Tam JS; Myles PR;
    Lancet Respir Med; 2014 Jul; 2(7):e10-2. PubMed ID: 24948433
    [No Abstract]   [Full Text] [Related]  

  • 60. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
    Antes G; Meerpohl JJ
    Lancet Respir Med; 2014 Jul; 2(7):e10. PubMed ID: 24948429
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.